secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tango Therapeutics, Inc. (TNGX)
CIK:        0001819133
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0000950170-24-055062
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tango Therapeutics Q1 2024 net loss $37.9M ($0.35/sh); cash $343.6M funds into late 2026
--------------------------------------------------------------------------------

- Net loss of $37.9M, or $0.35 per share, vs $28.0M ($0.32) in Q1 2023.
- Cash, equivalents and marketable securities of $343.6M as of March 31, 2024.
- R&D expense rose to $38.1M from $28.0M due to clinical program advancement.
- Dose expansion initiated for TNG908 (PRMT5 inhibitor) in MTAP-deleted tumors.
- PRMT5 clinical data update expected in 2H 2024; TNG462 expansion expected Q2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1819133/000095017024055062/0000950170-24-055062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1819133/000095017024055062/tngx-20220810.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-055062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer